Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
C1-esterase inhibitor (Berinert®) is recommended as an option for use within NHS Wales for the treatment of acute episodes of hereditary angioedema type I and II. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | C1-esterase inhibitor (Berinert®) | ||
| Formulation | 500 units powder and solvent for solution for injection / infusion | ||
| Reference number | 1425 | ||
| Indication | Treatment of acute episodes of hereditary angioedema type I and II (HAE) |
||
| Company | CSL Behring UK Ltd | ||
| BNF chapter | Respiratory system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1613 | ||
| NMG meeting date | 15/05/2013 | ||
| AWMSG meeting date | 12/06/2013 | ||
| Ratification by Welsh Government | 29/07/2013 | ||
| Date of issue | 31/07/2013 | ||
| Date of last review | 30/09/2016 | ||
| Commercial arrangement | WPAS | ||